Le Lézard
Classified in: Health, Science and technology

BioGX Candida Auris PCR Assay Adoption Accelerates

BIRMINGHAM, AL / ACCESSWIRE / March 23, 2023 / BioGX, a global provider of easy molecular diagnostic solutions, announced accelerated adoption of their high performance Sample-Ready™ PCR assay* for detection of Candida auris, a rapidly spreading, hard to treat fungus with a growing presence in hospitals and long-term care facilities. A complete PCR mix is provided in a single lyophilized tube format to be validated by laboratories on a variety of real-time PCR instruments including the BD MAX™, ThermoFisher QuantStudio™, BioRAD CFX Touch™ and the new BioGX pixl™ platform.

"Our platform agnostic Candida auris PCR assay has been successfully validated and implemented by public health laboratories and hospitals in several states," said Shahin Iqbal, PhD, BioGX President & COO." He further added, "We are grateful that laboratories trust us to address their unmet needs for detection of emerging pathogens."

Dr. Margie Morgan, Director, Clinical Microbiology Pathology and Laboratory Medicine at Cedars Sinai Hospital said "the BioGX Candida auris PCR assay provides a rapid and sensitive method to perform surveillance testing for our patient population. The real time results have been used by our Epidemiology team to institute timely isolation precautions to successfully prevent C. auris transmission in our medical center."

BioGX's Sample-Ready™ line of products offer custom manufactured or Research Use Only PCR assays, lyophilized in a single vial and fine-tuned to ensure high performance across multiple platforms that are commonly used in laboratories today.

Additional information can be requested by contacting BioGX at Ph: + or info@biogx.com.

*Research Use Only, Not intended for human or animal diagnostic use.

Sample-Ready, Just Add Water, Xfree and pixl are trademarks of BioGX, Inc.

About BioGX

BioGX is a leading global provider of lyophilized real-time PCR reagents for molecular diagnostics. BioGX, Inc., headquartered in Birmingham, Alabama and Dallas, TX, and its wholly owned subsidiary BioGX B.V., based in Amsterdam, The Netherlands, (collectively "BioGX"), operates in a cGMP compliant environment certified to ISO 13485 medical device development and manufacturing standards. For more information, visit BioGX.com.

Contact Information:

Mohammed Merchant
Sr. Director, Marketing
(205) 250-8055



View source version on accesswire.com:

These press releases may also interest you

at 13:00
Generational Capital Markets (GCM) Member FINRA/SIPC and a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client Youngblood Air Systems (dba Youngblood Automation, Inc.) to H&P...

at 12:52
The buzz about a potential recession has been overpowered lately by talk about a related warning signal - delinquent payments. TransUnion predicts that over the course of 2023, serious credit card delinquencies will rise by 24% to levels not seen...

at 12:50
Scope AR, a pioneer of enterprise-class augmented reality solutions for work instructions and remote assistance, announced today that they are collaborating on new market opportunities for smart glasses leveraging Snapdragon Spacestm XR Developer...

at 12:45
Infinite Electronics, a global portfolio of leading in-stock connectivity solution brands, will have more than 11,000 trees planted in partnership with One Tree Planted, a nonprofit organization that focuses on reforestation. This is the result of a...

at 12:45
The "Global Extended Reality Display Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Solution, Application, End-User, Region" report has been added to ResearchAndMarkets.com's offering. Extended Reality (XR) is the combination of...

at 12:40
Plastic pollution, climate change and biodiversity loss are highly intertwined and exacerbate each other, threatening our life...

News published on and distributed by: